What You Should Know: - Merck, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. - MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck. MDSS Accelerator Program Focus The MDSS is a collaboration between
Read More
PwC Report: 5 Key Actions for Pharma Companies to Drive Value Growth
What You Should Know: - A new PwC report offers insights into how pharma companies can translate game-changing science into greater returns. - Despite many major therapeutic advancements within the last decade, returns from pharma companies lagged the S&P 500 by about one-third and biotech underperformed by 60 percent. The stock performance divide between the front and back of the pack has been widening. PwC’s analysis showed that in 2021, the five-year
Read More
Phenomix Sciences Launches Obesity Biobanking Registry Studying Personalized Treatment Options Based on Genetics
What You Should Know: - Biotech company Phenomix Sciences launches its biobanking registry, marking the first obesity registry to study the impact of personalized treatment based on phenotyping. The impact of this biobanking registry and the data it will yield has the potential to change the entire system’s approach to obesity, from a treatment recommendation to the way payers determine coverage and how the industry combines diagnostics testing with drug therapy. - The
Read More
Genetics Startup Pleno Launches Out of Stealth with $15M
What You Should Know: - Pleno, a multi-omics startup, is emerging out of stealth with a $15M Pre-Series A financing and Greg Lucier as Chairman of the Board of Directors. Founded by Pieter van Rooyen, a well-known biotech engineer who built and sold his last company, Edico Genome, to Illumina for $100M. Edico's Dragen technology has become a staple in genetics research. - Pleno's Hypercoding technology has the potential to revolutionize biological target detection for
Read More
Cerner Collaboration to Increase Access to Cancer Clinical Trials
What You Should Know: - Cerner, Elligo Health Research® and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. - Together they will be using the research-activated network of health systems, real-world data (RWD) and multiomics technology, developed by Freenome, with the goal to help accelerate early cancer detection. Importance of Early Cancer Detection Early
Read More
Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines
What You Should Know: - Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines. - Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and dose-limiting toxicities. By enabling precisely targeted, highly efficient, manufacturable “off-the-shelf” in
Read More
3 Keys to Eliminating Data Breakdowns in Life Sciences
Across life sciences, experts boldly predict that data is the new currency—and that mobilizing data from clinical trials, wearable devices and even social media will ignite innovation in 2022. But leveraging data for innovation depends not just on data analytics, but also access to the right data and timely analysis. As the amount of data that life sciences experts have at their fingertips explodes, with leaders tapping into real-world evidence from smartphone apps, wearable devices and
Read More
VivoSense Raises $25M for Wearable Sensor Biomarkers to Advance Clinical Trials
What You Should Know: - VivoSense, an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data raises $25 Million in Series A funding. - The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital
Read More
Tempus Launches Pathology-Driven AI Platform
What You Should Know: - Tempus, a provider of artificial intelligence and precision medicine, today announced the launch of Edge, an innovative platform that allows pathologists to access developing AI models intended to identify specimens with potentially actionable biomarkers using a single hematoxylin and eosin stain (H&E) slide. - With access to over 50 petabytes of de-identified multimodal data, Tempus is developing AI models with the aim to identify patients who would
Read More
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can
Read More
